GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Global Biotech Inc (ROCO:6808) » Definitions » Debt-to-EBITDA

3D Global Biotech (ROCO:6808) Debt-to-EBITDA : -0.31 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is 3D Global Biotech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

3D Global Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$6.30 Mil. 3D Global Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$4.08 Mil. 3D Global Biotech's annualized EBITDA for the quarter that ended in Dec. 2023 was NT$-33.65 Mil. 3D Global Biotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.31.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for 3D Global Biotech's Debt-to-EBITDA or its related term are showing as below:

ROCO:6808' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.87   Med: -0.29   Max: -0.01
Current: -0.29

During the past 7 years, the highest Debt-to-EBITDA Ratio of 3D Global Biotech was -0.01. The lowest was -0.87. And the median was -0.29.

ROCO:6808's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.36 vs ROCO:6808: -0.29

3D Global Biotech Debt-to-EBITDA Historical Data

The historical data trend for 3D Global Biotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Global Biotech Debt-to-EBITDA Chart

3D Global Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.15 -0.87 -0.60 -0.29 -0.29

3D Global Biotech Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 -0.53 -0.23 -0.36 -0.31

Competitive Comparison of 3D Global Biotech's Debt-to-EBITDA

For the Biotechnology subindustry, 3D Global Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3D Global Biotech's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Global Biotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where 3D Global Biotech's Debt-to-EBITDA falls into.



3D Global Biotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

3D Global Biotech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.297 + 4.082) / -35.846
=-0.29

3D Global Biotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.297 + 4.082) / -33.65
=-0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


3D Global Biotech  (ROCO:6808) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


3D Global Biotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of 3D Global Biotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


3D Global Biotech (ROCO:6808) Business Description

Traded in Other Exchanges
N/A
Address
No.99, Sec. 1, Xintai 5th Rd, 21st Floor -3, Xizhi District, New Taipei, TWN, 221
3D Global Biotech Inc is engaged in developing reconstruction of human tissues and organs and manufactures customized and personalized high-level medical devices.

3D Global Biotech (ROCO:6808) Headlines

No Headlines